linked to diminished promoter activity), and identify rs34481144 genotype-specific differences in transcription-factor binding to the IFITM3 promoter. Of particular importance, the rs34481144-A (risk) allele increases binding of the methylation-sensitive CTCF transcriptional repressor, which has not previously been linked to the regulation of IFITM3 expression.
CTCF promoter binding is disrupted by DNA methylation, and interestingly, the rs34481144-A (risk) allele ablates a CpG methylation site in the IFITM3 promoter. In their final set of experiments, Allen et al. 2 examined the relationship between the rs34481144 genotype, IFITM3 promoter methylation, CTCF promoter binding, and IFITM3 expression in cell types relevant to influenza disease in humans. Their observations are consistent with the notion that the rs34481144 genotype controls IFITM3-promoter methylation in memory CTLs. As such, their findings support a model in which methylation at the rs34481144 locus reduces CTCF binding to increase IFITM3 expression, which leads to increased memory CTL survival and more efficient viral clearance from infected airways (Fig. 1) . Therefore, although a previous study suggested that IFITM3 expression is important for memory CTL survival during secondary influenza virus challenge 3 , the work presented by Allen et al. 2 provides the first evidence that a human allele associated with influenza-disease severity directly regulates IFITM3 expression in this cell type.
The identification of host genetic polymorphisms that regulate risk for severe influenza disease is imperative for reducing influenzaassociated morbidity and mortality. Until now, no studies have confidently linked a human genetic variant with influenza disease risk and directly established its mechanism of action.
of the IFITM3 gene (rs12252-C) was previously shown to increase influenza disease severity in some individuals [4] [5] [6] [7] [8] , but the underlying mechanism remains ambiguous.
To identify new IFITM3-associated SNPs that might have the potential to influence influenza disease severity, Allen et al. 2 first assembled candidate SNPs located in the IFITM3 core promoter and coding regions, and then prioritized those candidates according to common allele frequency in European populations and putative functional attributes. A single SNP (rs34481144), located in the IFITM3 promoter region, satisfied their prioritization criteria. Genotyping analysis of three different patient cohorts revealed statistically significant associations of the rs34481144-A (risk) allele with more severe disease symptoms, earlier virus replication in nasal tissue, and pediatric mortality. Combining data from all three patient cohorts, the authors estimated that individuals carrying the rs34481144-A (risk) allele are ~2.6 times more likely to experience a severe outcome upon influenza virus infection.
Given the location of rs34481144 in the IFITM3 core promoter and the rs34481144-A (risk) allele's association with lower IFITM3 expression in blood cells (according to the authors' query of expression quantitative trait loci data, available through the GenotypeTissue Expression project; https://www.gtexportal.org/), it seems likely that rs34481144 controls influenza disease risk by regulating IFITM3 expression levels. Allen et al. 2 provide substantial data to support an association between the rs34481144-A (risk) allele and reduced IFITM3 expression in immune cells responding to influenza virus infection. They further demonstrate that the rs34481144 genotype directly affects IFITM3 promoter function (wherein the rs34481144-A (risk) allele is Influenza viruses can cause severe and sometimes fatal disease in humans, owing to differences in the pathogenicity of individual virus strains and variation in human susceptibility. Risk factors-including age, underlying comorbidities, and pregnancy-influence susceptibility, but do not explain all of the circumstances under which serious influenza-associated complications occur 1 . Host genetic factors have emerged as potential regulators of human influenza disease susceptibility, and these may explain severe disease in otherwise apparently healthy individuals. In this issue of Nature Medicine, Allen et al. 2 reveal a new single-nucleotide polymorphism (SNP) risk allele in the gene IFITM3 that is strongly associated with severe influenza disease, and further detail a novel mechanism through which this SNP regulates IFITM3 expression to influence the survival of CD8 + T lymphocytes (CTLs) (Fig. 1) .
IFITM3 is induced by interferons and is a strong candidate for genetic regulation of human influenza susceptibility because of its ability to inhibit influenza virus replication in vitro and to restrict influenza virus pathogenicity in mice. It also shapes adaptive immune responses to influenza by protecting memory CTL survival during secondary influenza virus challenge 3 . A SNP in the coding region n e w s a n d v i e w s capable of binding IFITM3 on sites overlapping the rs34481144 locus. Most critically, future efforts must focus on the development of large, well-powered cohort(s) that include people with various human ancestries, both for the wider validation of the rs34481144 allele and for the identification of other SNPs that regulate human influenza disease. Ideally, these cohorts should include individuals that have been infected with different influenza viruses, because susceptibility may vary depending on the type of influenza virus strain contracted (for example, seasonal human H1N1 as opposed to avian H5N1 viruses). Moreover, the identification and inclusion of patients who have experienced asymptomatic infections could assist in the identification of resistance alleles. Given the time and expense required for the development of such cohort(s), emphasis should also be placed on new animal models that more closely represent human influenza disease (for example, the Collaborative Cross or Diversity Outbred mice) as a means of identifying potential susceptibility alleles that can be further examined in limited patient cohorts. Ultimately, the identification of genetic risk factors that regulate influenza disease susceptibility may improve clinical case management by assisting in the identification of individuals who are at greater risk for severe complications, and furthermore, may reveal crucial insights into influenza disease pathophysiology. The work reported by Allen et al. 2 is an important step toward achieving this goal.
Previously, targeted genetic analyses have associated the IFITM3 rs12252-C allele with severe influenza disease, particularly in populations with Asian ancestry 5, 6 , but mechanistic information is lacking. Other attempts at targeted genetic analysis have suggested potential riskfactor alleles in the CCR5 (ref. 12) ), no candidates have reached genome-wide significance; none have been authenticated through multiple studies or in multiple patient cohorts; and few attempts to identify mechanisms have been performed. In their work, Allen et al. 2 used a targeted approach to identify a SNP (rs34481144) that regulates the expression of IFITM3. The association of the rs34481144-A (risk) allele with higher influenza disease severity across three different patient cohorts, as well as detailed mechanistic studies, provides substantial credibility to their finding, which clearly surpasses the limitations of previous work.
Future studies based on the current work should address several open questions to fully clarify how rs34481144 contributes to human influenza disease. IFITM3 protein limits influenza virus infection in cell types other than CTLs that are central to influenza pathogenicity (for example, epithelial and endothelial cells), so potential contributions of these cell types to rs34481144-regulated disease severity need to be examined carefully. At the molecular level, mechanistic insights may be garnered by evaluating the effects of rs34481144 on global IFITM3 promoter occupancy, given that Allen et al. 2 described effects for only a small subset of transcription factors Figure 1 The rs34481144 allele regulates IFITM3 expression and influenza severity. (a) Allen et al. 2 show that a G (protective) allele in the IFITM3 promoter promotes the methylation of an adjacent nucleotide, whereas the A (risk) allele ablates methylation. They show that methylation blocks binding of the CTCF transcriptional repressor, allowing transcription to occur, whereas in the absence of methylation, CTCF binds to the IFITM3 promoter and represses IFITM3 transcription. (b) Allen et al. 2 further show that IFITM3-promoter methylation promotes IFITM3 protein expression in memory CTLs, which protects CTL survival after influenza virus challenge. CTL, CD8 + T lymphocyte.
